详文均见于”最近进展”（除非另有说明）; 同一文章可能见于本节内不同分类
Full articles can be found under “Recent Progress” unless specified; same reports may be classified under different categories in this section
乳腺癌 Breast cancer
1/18/2025: FDA 批准 datopotamab deruxtecan-dlnk 用于治疗不可切除或转移性, HR 阳性、HER2 阴性乳腺癌 FDA approves datopotamab deruxtecan-dlnk for unresectable or metastatic, HR-positive, HER2-negative breast cancer
1/5/2025: 蒽环类药物对复发评分>31淋巴结阴性 HR+/HER2- 乳腺癌的影响 Impact of anthracyclines in RS >31 node-negative HR+/HER2- breast cancer
1/4/2025: 新一代雌激素受体降解剂Imlunestrant+/-阿贝西尼治疗晚期乳腺癌 Next-generation ER degrader with or without abemaciclib for advanced breast cancer
肺癌 Lung cancer
2/17/2025: Zenocutuzumab 对 NRG1 融合阳性肺癌和胰腺癌的疗效 Efficacy of Zenocutuzumab in NRG1 fusion-positive non-small cell lung cancer and pancreatic cancer
1/12/2025: Metformin (二甲双胍)对肥胖症和肺癌预后和免疫治疗效果的改善 Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin
结直肠癌 Colorectal cancer
3/9/2025: Invikafusp Alfa 用于PD-(L)1进展的结直肠癌 Invikafusp Alfa in PD-(L)1 refractory colorectal cancer
1/11/2025: 年轻人与老年人的结肠直肠癌发病率趋势：癌症登记数据分析 Colorectal cancer incidence trends in younger versus older adults: population-based cancer registry data
肛门癌 Anal cancer
3/2/2025: 肛门鳞状细胞癌的放射治疗：ASTRO 实践指南 Radiation therapy for anal squamous cell carcinoma: An ASTRO practice guideline
胰腺癌 Pancreatic cancer
2/17/2025: Zenocutuzumab 对 NRG1 融合阳性肺癌和胰腺癌的疗效Efficacy of Zenocutuzumab in NRG1 fusion-positive non-small cell lung cancer and pancreatic cancer
神经内分泌肿瘤 Neuroendocrine tumor
2/22/2025: 卡博替尼治疗晚期神经内分泌肿瘤的 III 期试验 Phase III trial of cabozantinib in advanced neuroendocrine tumors
1/26/2025: 依维莫司联合lanreotide相比于依维莫司单药治疗不可切除或复发性胃肠胰神经内分泌肿瘤 Everolimus combined with lanreotide versus everolimus monotherapy for unresectable or recurrent gastroenteropancreatic neuroendocrine tumor
前列腺癌 Prostate cancer
3/15/2025: Talazoparib + 恩杂鲁胺一线治疗转移性去势抵抗性前列腺癌改善生存率 Talazoparib + enzalutamide as first-line treatment in metastatic castration-resistant prostate cancer (mCRPC) improved survival : TALAPRO-2 trial
子宫内膜癌 Endometrial cancer
2/1/2025: 帕博利珠单抗联合辅助化疗（联合或不联合放疗）治疗高风险错配修复缺陷型子宫内膜癌 Pembrolizumab plus adjuvant chemotherapy +/- Radiotherapy for high-risk endometrial cancer: results in dMMR Tumors
宫颈癌 Cervical Cancer
3/16/2025: 帕博利珠单抗联合放化疗，随后使用帕博利珠单抗一线治疗局部晚期宫颈癌 Pembrolizumab owith chemoradiotherapy followed by pembrolizumab for newly diagnosed locally advanced cervical cancer: KEYNOTE-A18
鼻咽癌 Nasopharyngeal cancer
2/9/2025: 帕博利珠单抗联合或不联合贝伐单抗治疗铂类耐药性鼻咽癌 Pembrolizumab with or without bevacizumab in platinum-resistant nasopharyngeal carcinoma (NPC)
黑色素瘤 Melanoma
3/8/2025: 纳武单抗+伊匹单抗用于抗 PD-1 治疗进展后的黑色素瘤脑转移 Intracranial outcome of ipilimumab and nivolumab for melanoma brain metastases following progression on anti–PD-1
3/1/2025: 伊匹单抗联合纳武单抗与单独使用纳武单抗治疗黑色素瘤脑转移患者：一项随机 II 期研究的 7 年随访 Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases: 7-year follow-up of a randomized, phase II study
淋巴瘤 Lymphoma
2/23/2025: 新型 CD19-1XX 嵌合抗原受体在大 B 细胞淋巴瘤中具有校准信号传导的首次人体 研究 First-in-human study of a novel CD19-1XX chimeric antigen receptor with calibrated signaling in large B-cell lymphoma
2/8/2025: BRUIN研究Pirtobrutinib治疗Richter转化的亚组分析 Subset analysis in BRUIN trial of Pirtobrutinib treating Richter transformation
肉瘤 Sarcoma
1/25/2025: Siremadlin 和 ribociclib 用于晚期脂肪肉瘤 Siremadlin and ribociclib used in advanced liposarcoma
脑膜瘤 Brain Tumor
1/19/2025: 177Lu-Dotatate 对手术和放射治疗无效的脑膜瘤患者的前瞻性 II 期研究 A prospective, phase II study of 177Lu-dotatate in Patients with surgery- and radiation-Refractory meningioma
肿瘤生物学和治疗/诊断新进展 Tumor biology & New treatment/diagnosis progress
3/9/2025: Invikafusp Alfa 用于PD-(L)1进展的结直肠癌 Invikafusp Alfa in PD-(L)1 refractory colorectal cancer
2/23/2025: 新型 CD19-1XX 嵌合抗原受体在大 B 细胞淋巴瘤中具有校准信号传导的首次人体 研究 First-in-human study of a novel CD19-1XX chimeric antigen receptor with calibrated signaling in large B-cell lymphoma
2/17/2025: Zenocutuzumab 对 NRG1 融合阳性肺癌和胰腺癌的疗效 Efficacy of Zenocutuzumab in NRG1 fusion-positive non-small cell lung cancer and pancreatic cancer
流行病学 Epidemiology
2/2/2025: 多民族队列研究细颗粒物 (PM2.5)和乳腺癌发病率 PM2.5 and Breast Cancer Incidence in the Multiethnic Cohort Study